1	<u>Remote Monitoring of AF Recurrence using mHealth Technology (REMOTE-AF)</u>				
2	Adasuriya G ¹ , Barsky A ^{3,4} , Kralj-Hans I ¹ , Mohan S ¹ , Gill S ³ , Chen Z ¹ , Jarman J ¹ , Jones D ¹ ,				
3	Valli H^1 , Gkoutos $G^{3,4}$, Markides V^1 , Hussain W^1 , Wong $T^{1,2,6}$, Kotecha, $D^{3,5}$, Haldar S^1 , on				
4	behalf of the REMOTE-AF and CASA-AF trial groups, the cardAIc team and the				
5	BigData@Heart Consortium*				
6					
7	1. Heart Rhythm Centre, Royal Brompton and Harefield Hospitals, Guy's and St				
8	Thomas' NHS Foundation Trust, London, UK.				
9	2. National Heart and Lung Institute, Imperial College London, London, United				
10	Kingdom				
11	3. Health Data Research UK Midlands, University Hospitals Birmingham NHS				
12	Foundation Trust, Birmingham, UK				
13	4. Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham,				
14	UK				
15	5. Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.				
16	6. Kings College Hospital, London, UK.				
17	*See acknowledgements.				
18					
19	<u>Short Title:</u>				
20	REMOTE-AF				
21					
22	Corresponding Author:				
23	Dr Shouvik Haldar				
24	Harefield Hospital				
25	Hill End Road				

Page 🗕

26 l	Uxbridge,	UB9	6JH
------	-----------	-----	-----

- 27 Email: s.haldar@rbht.nhs.uk
- 28

29	Study Registration:
30	ClinicalTrials.gov Identifier: NCT05037136
31	https://clinicaltrials.gov/ct2/show/NCT05037136
32	
33	Total Word Count (Excluding Tables and Figures)
34	4605
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	

.

51 Abstract

75

52 Background:

53	Atrial Fibrillation (AF) detection tools have rapidly developed over the last decade alongside
54	the evolution of mobile health (mHealth) monitoring. mHealth wearable technologies have
55	been hypothesised to be a potential non-invasive and near continuous modality for long term
56	detection and monitoring of atrial arrhythmias. We conducted a proof-of-concept study to
57	evaluate changes in heart rate obtained from a consumer wearable device and compare
58	against implanted loop recorder (ILR)-detected recurrence of AF and atrial tachycardia (AT)
59	after AF ablation.
60	
61	Methods:
62	REMOTE-AF (Remote Monitoring of AF Recurrence Using mHealth Technology;
63	NCT05037136) was a prospectively designed sub study of the CASA-AF randomised
64	controlled trial (NCT04280042). Participants without a permanent pacemaker had an ILR
65	implanted at their index ablation procedure (catheter vs thoracoscopic) for longstanding
66	persistent AF. Heart rate (HR) and step count were continuously monitored using a wrist-
67	worn wearable device connected to a smartphone. Photoplethysmography (PPG) recorded
68	HR data was pre-processed with noise filtration and episodes at 1 -minute intervals over 30
69	minutes of HR elevations (Z-score = 2) were compared to corresponding ILR data.
70	Arrhythmias detected by ILR were validated by an independent cardiac physiologist. The AF
71	Effect on Quality of Life (AFEQT) questionnaire was completed by participants at baseline
72	and at the conclusion of the study.
73	
74	

76 **Results:**

77	Thirty-five patients were enrolled, with mean age 70.3 +/- 6.8 yrs, 12 (34%) women, and
78	median follow-up 10 months (IQR 8-12 months). ILR analysis revealed 17 out of 35 patients
79	(49%) had recurrence of AF/AT. Compared with ILR recurrence, wearable-derived
80	elevations in HR \geq 110 beats per minute had a sensitivity of 95.3%, specificity 54.1%,
81	positive predictive value (PPV) 15.8%, negative predictive value (NPV) 99.2% and overall
82	accuracy 57.4%. With PPG recorded HR elevation spikes (non-exercise related), the
83	sensitivity was 87.5%, specificity 62.2%, PPV 39.2%, NPV 92.3% and overall accuracy
84	64.0% in the entire patient cohort. In the AF/AT recurrence only group, sensitivity was
85	87.6%, specificity 68.3%, PPV 53.6%, NPV 93.0% and overall accuracy 75.0%.
86	
87	Conclusion:
88	Consumer wearable devices have the potential to contribute to arrhythmia detection after AF
89	ablation, but further work is needed to improve and validate new composite detection
90	algorithms.
91 92 93 94	<u>Non Standard Abbreviations and Acronyms:</u> AF – atrial fibrillation
95	AFEQT – atrial fibrillation effect on quality of life
96	AI – artificial intelligence
97	API – application programming interface
98	AT – atrial tachycardia
99	AWS – amazon web services
100	EHRA – european heart rhythm association
101	ESC – european society of cardiology

102 EGM - electrogram

Page4

- 103 HCP healthcare professional
- 104 HR heart rate
- 105 HRS heart rhythm society
- 106 HRV heart rate variability
- 107 ILR implantable loop recorder
- 108 IQR interquartile range
- 109 LSPAF long standing persistent atrial fibrillation
- 110 mHealth mobile health
- 111 NICE national institute for health and care excellence
- 112 NPV negative predictive value
- 113 PHE public health england
- 114 PPG photoplethysmography
- 115 PPV positive predictive value
- 116 RADAR-base remote assessment of disease and relapses
- 117 SD standard deviation

118

119

- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127

128

129 Clinical Perspectives

130 What is New?

131	•	We have utilised a new composite of data obtained from wearable devices in a
132		predominantly older cohort of patients > 65 years old to detect AF/AT recurrence in a
133		long-standing persistent AF (LSPAF) patient population who have undergone AF
134		ablation.
135	•	We introduce a novel concept of the 'spike score', defined as the rate of change in HR
136		over a consecutive two-minute period to detect AF/AT recurrence.
137	•	This is the first study to have achieved this in a post AF ablation cohort of LSPAF
138		compared to the gold standard ILR.
139		
140	<u>Clinic</u>	cal Implications
141	•	The use of wearable devices to look for recurrence of atrial arrythmias in post ablation
142		cohorts may enable a more rapid time to detection for more timely interventions.
143	•	Data composites recorded from wearables may be used alongside the PPG waveform
144		to further improve accuracy in detecting atrial arrythmias.
145	•	AF/AT recurrence detected via wearable devices and associated smart mobile
146		applications can encourage risk factor modification through lifestyle interventions and
147		improve health literacy.
148		
149		
150		
151		
152		
153		

 ${}^{\mathsf{Page}}6$

154 Introduction

155	Atrial Fibrillation (AF) is one of the leading causes of cardiovascular morbidity and
156	mortality, increasing the risk of thromboembolism, heart failure and confers a five times
157	increased risk of stroke. ¹ Over 37 million people globally have a diagnosis of AF with its
158	prevalence expected to double by 2060 leading to a significant economic burden. ² Given the
159	anticipated increasing health burden of AF, it is a public heath priority to identify patients
160	with AF and those with atrial arrhythmia recurrence post intervention. ³ The European Society
161	of Cardiology (ESC) AF 2020 guidelines advocate for an integrated care model to be utilised
162	in the diagnosis and management of AF. ¹ A key component of this model requires the use of
163	digital technology and mobile health (mHealth) solutions, to support both health care
164	professionals (HCPs) and patients in the comprehensive and personalised management of
165	health conditions. ⁴
166	
167	Modern and technologically advanced mHealth devices, specifically wearables, have
168	anonad as a nave and which it are and in an animality approximate a shutian to manitan
100	emerged as a new-age, ubiquitous and increasingly accurate solution to monitor
169	cardiovascular biometrics. ⁵ However, there is insufficient evidence to demonstrate their
169 170	cardiovascular biometrics. ⁵ However, there is insufficient evidence to demonstrate their utility in current clinical practice. Many published studies lack quality control and are
169 170 171	cardiovascular biometrics. ⁵ However, there is insufficient evidence to demonstrate their utility in current clinical practice. Many published studies lack quality control and are suboptimal in their design, exposing high risk for both selection and publication bias. ⁶
169 170 171 172	cardiovascular biometrics. ⁵ However, there is insufficient evidence to demonstrate their utility in current clinical practice. Many published studies lack quality control and are suboptimal in their design, exposing high risk for both selection and publication bias. ⁶ Nonetheless, this shift from physician to patient-driven monitoring using data from
169 170 171 172 173	cardiovascular biometrics. ⁵ However, there is insufficient evidence to demonstrate their utility in current clinical practice. Many published studies lack quality control and are suboptimal in their design, exposing high risk for both selection and publication bias. ⁶ Nonetheless, this shift from physician to patient-driven monitoring using data from personable wearable devices demonstrates potential and provides a unique opportunity to
169 170 171 172 173 174	emerged as a new-age, ubiquitous and increasingly accurate solution to monitor cardiovascular biometrics. ⁵ However, there is insufficient evidence to demonstrate their utility in current clinical practice. Many published studies lack quality control and are suboptimal in their design, exposing high risk for both selection and publication bias. ⁶ Nonetheless, this shift from physician to patient-driven monitoring using data from personable wearable devices demonstrates potential and provides a unique opportunity to identify clinically significant arrhythmias in post intervention patient cohorts. Many of these
169 170 171 172 173 174 175	emerged as a new-age, ubiquitous and increasingly accurate solution to monitor cardiovascular biometrics. ⁵ However, there is insufficient evidence to demonstrate their utility in current clinical practice. Many published studies lack quality control and are suboptimal in their design, exposing high risk for both selection and publication bias. ⁶ Nonetheless, this shift from physician to patient-driven monitoring using data from personable wearable devices demonstrates potential and provides a unique opportunity to identify clinically significant arrhythmias in post intervention patient cohorts. Many of these wearable devices utilise photoplethysmography (PPG) to monitor heart rate and
169 170 171 172 173 174 175 176	emerged as a new-age, ubiquitous and increasingly accurate solution to monitor cardiovascular biometrics. ⁵ However, there is insufficient evidence to demonstrate their utility in current clinical practice. Many published studies lack quality control and are suboptimal in their design, exposing high risk for both selection and publication bias. ⁶ Nonetheless, this shift from physician to patient-driven monitoring using data from personable wearable devices demonstrates potential and provides a unique opportunity to identify clinically significant arrhythmias in post intervention patient cohorts. Many of these wearable devices utilise photoplethysmography (PPG) to monitor heart rate and accelerometers to assist with signal processing to filter noise artefact. PPG leverages an
169 170 171 172 173 174 175 176 177	emerged as a new-age, ubiquitous and increasingly accurate solution to monitor cardiovascular biometrics. ⁵ However, there is insufficient evidence to demonstrate their utility in current clinical practice. Many published studies lack quality control and are suboptimal in their design, exposing high risk for both selection and publication bias. ⁶ Nonetheless, this shift from physician to patient-driven monitoring using data from personable wearable devices demonstrates potential and provides a unique opportunity to identify clinically significant arrhythmias in post intervention patient cohorts. Many of these wearable devices utilise photoplethysmography (PPG) to monitor heart rate and accelerometers to assist with signal processing to filter noise artefact. PPG leverages an optical technique to passively detect pulsatile volumetric changes in blood volume within the

7

 $\mathsf{Page}\mathsf{Z}$

Hence, artificial intelligence (AI) systems have been programmed into wearable devices to
accurately predict and detect atrial arrhythmias from PPG waveforms.⁹

181

182	In August 2020, the Heart Rhythm Society (HRS) in conjunction with the European Heart
183	Rhythm Association (EHRA) recognised the potential in the use of mHealth devices in
184	cardiovascular disease evaluation and designated it an important frontier in arrhythmia
185	management. ¹⁰ In addition, the European Society of Cardiology (ESC) has led the way in
186	incorporating the use of single lead ECG diagnosis of AF from mHealth devices into their
187	2020 guidelines for diagnosis and management of AF. ¹ However, the National Institute of
188	Clinical Excellence (NICE) in the United Kingdom has not yet recommended the use of
189	wearables in their recent AF diagnosis and management guideline (NG196) despite Public
190	Health England (PHE) sponsoring initiatives to promote the use of wearable technologies. ¹¹
191	
192	A multitude of research studies have assessed the ability of PPG to screen for asymptomatic
193	or index AF, however there is a paucity of data identifying recurrence of AF post rhythm
194	control intervention. Our study sought to evaluate the correlation between a novel composite
195	of wearable device recorded data with ILR (Reveal LINQ TM) detected AF/AT recurrence in a
196	cohort of patients who had undergone an AF ablation procedure for LSPAF.
197	

198 <u>Methods:</u>

199 *Study Design*

200 The REMOTE-AF study is a single arm, dual-centre, clinical study (NCT05037136)

201 exploring the validity of PPG recorded heart rate data being used in combination with

202 accelerometer derived step count data to predict the recurrence of atrial arrythmias in a post

ablation patient population. We labelled this combination as non-exercise related elevations

Page &

204	in HR, defined as a step count < 500 over a continuous 30-minute period. The literature does
205	not define 'non-exercise' in relation to step count, however a previous study accepted 100
206	steps per minute as 'moderate intensity' exercise and 2500 per day as a sedentary lifestyle. ¹²
207	The study was approved by the UK NRES ethical review board (20/NI/0089). Participants
208	were recruited from the Long Term Outcomes in CASA-AF study (RfPB NIHR200595,
209	ClinicalTrials.gov: NCT04280042) (Figure 1). ¹³ This was an extension of the CASA-AF trial,
210	where 120 adults with symptomatic LSPAF, naïve to previous interventions, EHRA symptom
211	score > 2 and left ventricular ejection fraction \geq 40 were recruited between September 2015
212	and June 2018 and randomised to receive either radiofrequency catheter or thoracoscopic
213	surgical ablation for LSPAF. At the index procedure patients had an ILR (Reveal LINQ TM)
214	implanted which provided continuous cardiac monitoring with CARELINK remote
215	monitoring to assess arrhythmia recurrence over an initial 12 month follow up period which
216	was subsequently extended to 36 months. ¹⁴ The ILR had validated detection algorithm for
217	AF/AT. ¹⁵

218

219 *Study Participants*

We remotely recruited thirty-five patients, and all provided informed consent. Six eligible 220 221 participants who met the inclusion criteria (Table 1) declined to take part. Thirty-three 222 patients had ILRs in situ; two patients had dual chamber pacemakers instead of ILRs. Each participant was fitted with a wearable device (Fitbit Charge 2) and provided with a 223 224 smartphone (Samsung A2) at least 21 months after their index procedure. The remote assessment of disease and relapse (RADAR-base) data collection software and Fitbit mobile 225 226 application was pre-installed onto the smartphone to allow seamless integration with the Fibit 227 Charge 2 device sensors. The RADAR-base platform streamed data from the wearable, mobile application and smartphone to a central location.¹⁶ This platform was installed on a 228

 $P_{age}9$

virtual machine hosted on Amazon Web Services (AWS) in the AWS Europe (London)
region. Researchers were granted access to the Fitbit intraday developer application which
allowed automated data collection for registered participants through the RADAR-base
platform.

233

234 The A MEMS 3-axis accelerometer sensor enabled tracking of motion patterns and physical 235 activity whilst the optical wrist-based PPG sensor allowed tracking of heart rate. Participants 236 were encouraged to wear the wearable continuously, removing only during charging and 237 exposure to water, and to connect the Bluetooth enabled smartphone to the internet at least 238 once a day to allow synchronisation of data with the RADAR-base servers. At weekly 239 intervals, participants were reminded via text message to synchronise data if uploads had not 240 occurred and ad-hoc virtual meetings allowed troubleshooting of technical aspects. 241 Participants were asked to report any adverse effects (skin irritation, health anxiety or stress) related to the use of the wearable. Data was not collected beyond 31st January 2022. 242 243 244 Data Analysis 245 Heart rate and step count data recorded by the wearable were transmitted to the smartphone 246 mobile application via Bluetooth. PPG recorded HR data underwent signal processing and 247 was filtered for motion artefact using two accelerometer sensors. The RADAR-base

248 application was programmed to allow access to the Fitbit developer intraday application and

subsequently passively collected data and synchronised directly to a secure, encrypted cloud-

250 based web server. At the conclusion of the study, data was downloaded from the cloud server

- 251 onto a local server for analysis. The data included heart rate and step count time series
- 252 gathered from wearable devices and pooled at one-minute intervals. Mean heart rate data
- 253 was calculated for each individual participant at one-minute intervals over the duration of

 $_{\rm Page} 10$

254 follow up. We developed a method to detect sequences potentially suggestive of atrial 255 arrhythmia recurrence for each patient at thirty-minute overlapping intervals where heart rate 256 was at least two standard deviations (Z score \geq 2) above their mean for at least twenty 257 minutes and later excluded those that were exercise related. We extracted all of the available 258 tagged thirty-minute sequences for each patient (a total of 3208 sequences across our cohort) 259 and associated within these sequences heart-rate data with step data counterparts at the same 260 time points. Sequences were kept only where heart rate and step-count were both available 261 for the duration of the thirty-minute window. Each of these sequences were then stratified 262 into subcategories where corresponding step count values were denoted at 500 step intervals, 263 with further sub categorisation based on heart rate delta change. We used a simple yet reliable 264 method to identify time points where a participant's HR spiked. Across each sequence, we 265 searched for the greatest increase in HR across a two-minute interval and recorded the size of 266 that increase (in BPM). We termed this novel composite the "spike score". To compare 267 across patients, we computed the normalised spike score (or spike z-score), which is this 268 figure divided by the standard deviation of the patient's heart rate. We also computed the normalised downward spike score for each sequence, which is the largest two-269 270 minute decrease in a patient's heart rate that occurred after the upward spike. Normalised 271 spike scores ≥ 0.75 were taken to be indicators of sudden and significant heart rate elevation. 272 Each data sequence within each subcategory was compared to ILR data to denote if 273 recurrence of an atrial arrythmia had occurred. 274 275 For our analysis, a positive finding was recorded when our novel composite method for 276 AF/AT recurrence correlated with ILR detected electrogram (EGM) episodes showing 277 arrhythmia recurrence. If a text only episode of AF/AT was recorded by the ILR, we sought a

confirmatory EGM episode within a 24-hour period. ILR detected recurrences of atrial

Page 11

279	arrhythmia for at least 30 seconds were validated by a blinded senior cardiac physiologist.
280	One patient with no ILR detected AF/AT recurrence provided only three minutes of wearable
281	device data and therefore was excluded from our analysis.
282	
283	Study Outcomes
284	Our primary endpoint is the correlation between a composite of mHealth recorded heart rate
285	(PPG) and physical activity as denoted by step count and AF/AT recurrence as detected by
286	ILR. We analysed this in a stepwise manner:
287	
288	A) PPG recorded HR elevations (z score \geq 2) correlating with AF/AT recurrence as
289	detected by ILR.
290	B) PPG recorded HR elevations (z score \geq 2) combined with physical activity
291	correlating with AF/AT recurrence as detected by ILR.
292	C) PPG recorded HR elevations (z score ≥ 2) ≥ 110 beats per minute with normalised
293	spike score \geq 0.75 combined with physical activity correlating with AF/AT
294	recurrence as detected by ILR.
295	
296	Our secondary endpoint is the correlation between quality-of-life metrics as measured by the
297	AF quality-of-life questionnaire (AFEQT) score and ILR-detected AF/AT recurrence.
298	
299	Statistical Analysis
300	The sensitivity, specificity, NPV, PPV and accuracy and associated 95% confidence intervals
301	for detection of correlated atrial arrhythmias in individual study participants were calculated
302	using Microsoft Excel (Office 365, Microsoft Corporation, Washington, USA) with a

Page 🗕

significance level of 0.05. Missing data from the wearable, defined as lack of HR and step
count data for the entire 30-minute duration of identified sequences using the method
described above, were excluded from the extraction process and not included in final data
analysis.

307

308 **Results:**

309 The mean [SD] age of recruited patients was 70.3 $\left[+/-6.8\right]$ years with median 10 months [IQR 310 8-12] follow up (Table 2). Twenty-five patients completed at least six months follow up with 311 eight of these patients completing the full 15 month follow up. In total, 236,871 hours of data 312 were recorded via the wearable which amounts to a mean [SD] of 282 [+/-3.6] days per 313 participant. On average, participants recorded data during 80.6% of daytime hours (8am and 314 8pm) and 71.1% of night-time hours (8pm-8am). Implantable loop recorder analysis showed 315 48.6% (17/35 patients) had recurrence of AF/AT. The average AF Quality of Life Survey (AFEQT)¹⁷ score for patients in the non-AF/AT recurrence group was 48.9 at the beginning 316 317 of the study and 32.3 at the end of the follow up period, an improvement of 20% compared to 318 the AF/AT recurrence group who had scores of 45.0 pre study and 40.6 post study. 319 320 Analysis of our data in a stepwise manner showed PPG- recorded HR correlating with AF/AT 321 recurrence had a sensitivity of 95.3% (95%CI, 71-99); specificity 54.1% (95%CI, 50-59); 322 PPV 15.8% (95%CI, 4-27); NPV 99.2% (95%CI, 99-100) and accuracy 57.4% (95%CI, 323 52-63) (Table 3). Combining PPG- recorded heart rate and step count with AF/AT recurrence yielded a sensitivity of 93.2% (95%CI,68–99%); specificity 54.9% (95%CI, 49-60%), PPV 324 325 19.1% (95%CI, 6-18%); NPV 98.6% (95%CI, 97-99%) and accuracy 58.7% (95%CI, 52-

326 65%) (Table 3) (Figure 2 and 3). PPG recorded HR sequences identified by a normalised

spike score of 0.75 or above over 2 minutes for both onset of heart rate \geq 110 and cessation

Page 13

328	below 110 ov	er the same time	period produc	ed a sensitivity	of 87.5% ((95%CI.	63-99%);

- 329 specificity 62.2% (95%CI, 56-69%); PPV 39.2% (95%CI, 24-54%); NPV 92.3% (95%CI,
- 330 89-96%) and accuracy 64.0% (95%CI, 56-71%) (Table 3) (Figure 4). Focused assessment of
- the latter in the AF/AT recurrence group as defined by ILR led to a sensitivity of 87.6
- 332 (95%CI, 65-99%); specificity 68.3% (95%CI, 60-76%); PPV 53.6% (95%CI, 38-69%); NPV
- 333 93.0% (95%CI, 88-98%) and accuracy 74.0% (95%CI, 66-82%) (Table 3).
- 334

No adverse events such as skin irritation from wearable devices, health anxiety or stress were

reported by any of the 35 participants. Three wearable devices required strap replacement and

- resulted in 9 follow-up days lost.
- 338

339 **Discussion:**

340 REMOTE-AF evaluated the correlation between wearable device derived heart rate and

341 AF/AT recurrence. Current physician prescribed non-continuous rhythm monitoring tools

342 (ambulatory Holter monitors) which assess for arrhythmias at set time intervals are known to

have low detection yields.¹⁸ In symptomatic patients with suspected arrhythmias, a 24-hour

ambulatory Holter monitor has a diagnostic yield of 7% compared to 47% with a 7-day

345 monitor.¹⁹ At present, the gold standard for detection of atrial arrhythmias is continuous

346 monitoring via the implantable loop recorder (ILR). mHealth wearable devices can bridge the

347 gap between intermittent time limited Holter monitoring and invasive and costly ILR

348 monitoring.

349

350 To analyse our data, we adopted a stepwise approach to sequentially combine parameters

- from the wearable device. We saw an increase in PPV from 15.8% to 39.2% and
- improvement in accuracy from 57.4% to 64.0% when using our novel composite HR spike

353 score method compared to using PPG recorded HR alone to detect AF/AT recurrence. This is 354 because, the spike score is more likely to represent true arrhythmia rather than physiological 355 HR increase and hence more accurately differentiate between sinus tachycardia and 356 pathological recurrences of AF/AT. In patients with known AF/AT recurrence as detected by 357 ILR, our novel composite methodology utilising spike score resulted in the highest accuracy 358 in identifying AF/AT recurrence in a post ablation cohort when compared with ILR. 359 Irrespective of sequential improvements in accuracy, using this method results in 5 out of 10 360 episodes being misclassified as AF/AT. Further work with larger patient populations is 361 needed to improve the diagnostic accuracy of our method. Our results yielded a high NPV 362 and low PPV, likely due to our small sample size with low prevalence of AF/AT recurrence. 363 In clinical practice, this supports the use of wearables in high risk patient populations with 364 known diagnoses of atrial arrhythmias rather than for use in screening in low risk patient populations (global AF prevalence of 0.51%).² Our results also show that our novel 365 366 composite method in its current form, appropriately classifies non-recurrence of AF/AT but 367 occasionally misclassifies recurrence. Within the current consumer market, the diversity in 368 the accuracy and quality of PPG embedded in wearable devices limits the potential of integrating these data safely into the clinician's decision-making process.^{5,20} Extensive 369 370 research and funding has been dedicated to assessing the accuracy of PPG enabled wearables 371 in detecting atrial arrhythmias, predominantly AF screening but there remains a lack of data 372 in post AF intervention populations. Products developed by multi-billion-dollar global 373 technology giants have shown promise that wearable devices could become a viable 374 alternative in diagnosing and monitoring arrhythmias. The Apple Watch (Apple Inc, 375 Cupertino, CA, USA), Fitbit (Google LLC, Mountain View, CA, USA) and Huawei 376 Smartwatch (Huawei Technologies Co Ltd, Shenzhen, China) have been assessed in non-

randomised but large-scale prospective clinical trials, reporting accuracy of 95-97% in
 detecting AF and modest positive predictive values (PPV).²¹⁻²³

379

Our statistical analysis revealed a PPV significantly lower (Figure 5) than figures reported by 380 381 these landmark PPG detected arrhythmia studies, however these large-scale studies were 382 based on AF screening and not recurrence as in our cohort. Based on a recent meta-analysis, 383 these figures are likely to be unrealistically elevated, therefore our results are likely to be more representative of the accuracy of PPG in detecting AF/AT recurrence.⁶ Given there is 384 limited published data, predominantly case reports,²⁴⁻²⁷ documenting wearable use in rhythm 385 386 monitoring after catheter ablation we are unable to make a direct comparison of PPG enabled 387 wearables in this patient cohort. The reported clinical metric in the landmark studies only 388 analysed PPG HR waveforms intermittently whilst stationary, with the majority at night. We 389 reported results for all data both during active daytime hours and whilst ambulatory, where 390 clinically significant arrhythmias are more likely. Overall, our data provides greater real-391 world analysis, and highlights the issue of lower diagnostic yields and challenges related to 392 sensitivity and specificity of data from wearable devices during periods of activity. 393 Conducting this study during a global pandemic also produced its own challenges but further 394 advanced the necessity and accessibility for remote monitoring strategies, not just for western 395 populations but worldwide, to ensure health equity.

396

Recurrence of paroxysmal and persistent atrial arrhythmias which are rate -controlled are
likely to be misclassified as non-recurrence by our novel composite method. However, our
NPV consistently being above 90% for all analysed groups shows that this had a minimal
effect on our results. Our secondary endpoint showed that in patients with recurrence of atrial

401	arrhythmia, patients described a poorer quality of life as evidenced by a higher AFEQT score
402	when compared to the non-recurrence group. Consequently, our results demonstrate promise
403	in identifying atrial arrythmia recurrence by combining PPG- recorded, non-exercise related
404	elevations in heart rate with quality-of-life data. As a result, there is potential to avoid the
405	invasive nature of ILR insertion as well as labour and cost intensive follow up to achieve
406	long-term cost-effective monitoring. With further improvement in diagnostic accuracy, this
407	could lead to an electronic point- of- care notification being sent via a smart device to assist
408	pill in the pocket arrhythmia and anticoagulation management strategies as well as timely
409	interventions (DCCV or redo catheter ablation) in patients experiencing recurrence of atrial
410	arrythmias. ^{28,29} Lastly, due to our recruitment resulting in a homogenous population, more
411	heterogeneity with regards to ethnicity and gender is required to draw more specific
412	conclusions.
413	
414	To our knowledge, our study is the first to utilise a novel PPG derived HR spike score
415	methodology to detect AF/AT recurrence using gold- standard ILR technology as a
416	comparator. The ILR (Reveal LINQ [™]) used in this study was found to have an AF detection
417	sensitivity of 97.4%; specificity 97.0%; PPV 92.5%; NPV 99.0% and was able to detect AF
418	burden with a sensitivity of 98.4%. ¹⁵ Therefore, the ILR serves as an excellent comparator.
419	
420	The use of mHealth wearables to detect atrial arrhythmia recurrence is gaining traction and to
421	our knowledge REMOTE-AF is one of two studies, to report results for atrial arrythmia
422	recurrence in patients with a known history of AF, utilising PPG enabled wearable
423	technology. The other study utilised a smart ring to detect atrial arrythmia recurrence in a
424	patient cohort post DCCV. ³⁰ Currently active is the SMART-ALERT clinical trial which will
425	also use the ILR as a comparator for PPG -detected AF from a wearable device, both a

smartwatch and smart ring. Data from this study can be used to further support or refute the
use of PPG based wearables to detect atrial arrhythmias.³¹

428

Another study in progress is the SAFER (ISRCTN72104369)³² trial which will evaluate 429 430 evidence to support the tolerability and feasibility of screening patients > 65 years old using 431 PPG- enabled wearables. Our REMOTE-AF cohort with a mean age of 70.3 years and 432 median follow up at 10 months, has already clearly demonstrated acceptability and 433 tolerability in an older patient cohort. We recorded good compliance with device use and a 434 roughly equal proportion of use during day-time and night-time hours. Alongside results reported by the eBRAVE-AF trial (NCT04250220)²⁹ which screened for AF using 435 436 smartphone PPG sensors, this leads to greater confidence that digital wearable technology 437 can safely be used for not just screening but monitoring of known arrhythmia patients in the 438 cohort at greatest risk of AF and its complications. Limited economic analyses demonstrate 439 affordability and cost-savings associated with AF detection using wearables, specifically in 440 over-65s, further highlighting their potential to improve health outcomes as measured by quality-adjusted-life-years by enhancing primary and primordial prevention.^{33,34} 441

442

Incorporating heart rate variability (HRV) into our novel composite method would likely
have further improved our PPV as significant changes to HRV have been shown to correlate
with AF.³⁵ The Fitbit application programming interface (API) integrating HRV data was not
open to researchers at the commencement of the study therefore REMOTE-AF study team
did not have access to this data.

448

Future work requires more extensive investigation of PPG- enabled wearable devices and
arrhythmia detection tools in real-world clinical settings with the design of larger trials

451	including randomised clinical studies to report major adverse cardiovascular event (MACE)
452	outcomes. A reduction in time to detection of AF/AT recurrence would allow for more
453	responsive implementation of treatment strategies and lifestyle modifications to reduce
454	disease burden and improve quality of life. Consumer mHealth devices can also act to further
455	health literacy by facilitating patient understanding of disease progression and encourage
456	positive behaviour change to modify their risk profile. As PPG technology continues to
457	evolve, we can cautiously begin to consider this technology as an asset to improve clinical
458	outcomes and guide treatment decisions.
459	
460	We believe this proof- of- concept study can provide a foundation for further research and to
461	develop this method in conjunction with sophisticated algorithmic development tools to
462	inform a comprehensive diagnostic method to detect atrial arrhythmias with precision.
463	
464	Limitations
465	PPG technology itself has many limitations with the most prominent being motion artefact
466	and noise interference, which can disrupt arrhythmia detection algorithms and signal quality,
467	affecting the accuracy of heart rate measurements. ^{7,36} The devices used in the study were 2
468	years old with manufacturer recommended battery life of 4-5 days, however due to the
468 469	years old with manufacturer recommended battery life of 4-5 days, however due to the lithium polymer battery life, gradual deterioration resulted in patients charging devices every
468 469 470	years old with manufacturer recommended battery life of 4-5 days, however due to the lithium polymer battery life, gradual deterioration resulted in patients charging devices every 2-3 days which inevitably resulted in reduced compliance and more frequent interruptions to
468 469 470 471	years old with manufacturer recommended battery life of 4-5 days, however due to the lithium polymer battery life, gradual deterioration resulted in patients charging devices every 2-3 days which inevitably resulted in reduced compliance and more frequent interruptions to monitoring. The Fitbit Charge 2 is also only able to store data for 7 days before overwriting.
468 469 470 471 472	years old with manufacturer recommended battery life of 4-5 days, however due to the lithium polymer battery life, gradual deterioration resulted in patients charging devices every 2-3 days which inevitably resulted in reduced compliance and more frequent interruptions to monitoring. The Fitbit Charge 2 is also only able to store data for 7 days before overwriting. To minimise data loss, we sent weekly text reminders to participants whose data did not

likely have increased adherence. A similar data upload issue was noted with the ILR. The

475 Reveal LINQ[™] device can store EGM data for 27 minutes of patient activated episodes and

476 30 minutes of automatic detected episodes,³⁷ hence if multiple episodes are recorded over this
477 time period without being downloaded to the base device, data is overwritten.

478

479 A further major limitation of the study was the small sample size and that all participants 480 were Caucasian, potentially limiting the generalisability of our results. Sample size 481 limitations prevented us from being able to power our study to derive statistical significance 482 or draw wider conclusions applicable to a more diverse population. Given the exploratory 483 nature of our study, our pilot data shows promise for further work to be undertaken with a 484 sufficiently powered population size. Interruptions to ILR data upload via the CARELINK 485 remote monitoring software is also acknowledged as a major limitation. Dependent on the 486 frequency of arrhythmia recurrence, a more intensive download of ILR data would have been 487 required to capture all EGM episodes of detected AF/AT recurrence (that are then able to be 488 validated) rather than text only episodes. Our method of using text only episodes to confirm 489 ILR detected AF/AT recurrence is likely to have affected the sensitivity of our results and is 490 acknowledged as a significant limitation. In the two patients where we used pacemaker rhythm recording capabilities instead of ILR, we may have missed several episodes of AF/AT 491 492 recurrence as episodes not documented on pacing reports at three monthly device 493 interrogations had to be excluded. Furthermore, assessment of ILR EGMs was undertaken 494 by a single reviewer therefore we recognise possible misclassifications may have occurred. 495 Finally, the research team did not have access to raw PPG waveform or HRV data which 496 possibly led to a lower PPV. Applying the normalised spike score to raw PPG waveforms or 497 incorporating HRV data into our novel composite method may have led to improvements in PPV. 498

499

500	Future studies that use a large variety of data modalities, similar to those recorded in
501	REMOTE-AF, will need specific expertise in data handling and advanced data science due to
502	the complexity of data acquired from wearables. With appropriate training and education for
503	HCPs, it will enable a stepwise framework to incorporate high-value AI into routine
504	cardiovascular care. ³⁸

505

506 **Conclusion:**

507 Our novel composite of wearable device data (PPG recorded heart rate data, HR spike score

and step count) is a promising and modest predictor of AF/AT recurrence, in a post-ablation

509 cohort compared to the gold standard ILR. Further work is required to determine whether

510 consumer wearables integrating HR and step count with advanced algorithmic detection tools

511 can improve AF/AT detection and guide treatment strategies.

512

513 Acknowledgements:

514 We would like to thank the CASA-AF research team at the Royal Brompton and Harefield

515 Hospitals and the cardAIc team at the University of Birmingham/University Hospitals

516 Birmingham NHS Foundation Trust for set up of the study, as well as Grace Augustine

517 (senior cardiac physiologist at Kettering General Hospital NHS Foundation Trust) for helping

518 with the validation using ILR. We would also like to thank Julia Kurps, Joris Borgdorff and

519 Nivethika Mahasivam at the Hyve (Utrecht, The Netherlands) for providing technology

support, the RADAR-base team (Richard Dobson, Amos Folarin, Yatharth Ranjan, Pauline

- 521 Conde, Callum Stewart and Zulqarnain Rashid at King's College London, UK) and the
- 522 BigData@Heart Consortium (Lead: Diederick E Grobbee, University Medical Centre
- 523 Utrecht, The Netherlands; Scientific Coordinator: Folkert W Asselbergs, University of
- 524 Amsterdam, The Netherlands).

525 Sources of Funding:

526	REMOTE-AF study did not receive formal funding. Smart devices and the technology used
527	in the trial were provided by the University of Birmingham as part of funding from an
528	Innovative Medicines Initiative European Union Horizon 2020 grant under agreement
529	number 116074 (BigData@Heart; https://www.bigdata-heart.eu/)'supported by the European
530	Union's Horizon 2020 research and innovation programme and European Federation of
531	Pharmaceutical Industries and Associations. The cardAIc team at the University of
532	Birmingham/University Hospitals Birmingham NHS Foundation Trust have received funding
533	from the National Institute for Health Research (NIHR) Birmingham Biomedical Research
534	Centre (NIHR203326), MRC Health Data Research UK (HDRUK/CFC/01), NHS Data for
535	R&D Subnational Secure Data Environment programme, and a British Heart Foundation
536	Accelerator Award (AA/18/2/34218). The funders had no role in considering the study design
537	or in the collection, analysis, interpretation of data, writing of the report, or decision to
538	submit the article for publication. The opinions expressed in this study are those of the
539	authors and do not represent the EU, NIHR, UK Department of Health and Social Care, or
540	any of the listed institutions.

541

542 **Disclosures**:

- 543 SG reports funding through the BigData@Heart Innovative Medicines Initiative [grant no.
- 544 116074]. AB reports funding from the BigData@Heart Innovative Medicines Initiative [grant
- no. 116074] during the conduct of the study. DK reports grants from the National Institute for
- Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK;
- 547 NIHR132974 D2T-NeuroVascular; NIHR203326 BRC), the British Heart Foundation
- 548 (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), the EU/EFPIA Innovative
- 549 Medicines Initiative (BigData@Heart 116074), EU Horizon (HYPERMARKER 101095480),

 ${}^{\rm Page}22$

550 UK National Health Service -Data for R&D- Subnational Secure Data Environ

- 551 programme, and the European Society of Cardiology supported by educational grants from
- 552 Boehringer Ingelheim/BMS-Pfizer Alliance/Bayer/Daiichi Sankyo/Boston Scientific, the
- 553 NIHR/University of Oxford Biomedical Research Centre and British Heart
- 554 Foundation/University of Birmingham Accelerator Award (STEEER-AF). In addition, he
- has received research grants and advisory board fees from Bayer, Amomed and Protherics
- 556 Medicines Development; all outside the submitted work. GG reports support from the NIHR
- 557 Birmingham Experimental Cancer Medicine Centre, NIHR Birmingham Surgical
- 558 Reconstruction and Microbiology Research Centre, Nanocommons H2020-EU (731032), and
- the MRC Heath Data Research UK (HDRUK/CFC/01). SH reports speaker fees from
- 560 Alivercor, consultancy fees from BMS, a research grant from Abbott and the NIHR grants
- 561 (CASA and LOTO).
- 562 GA, IKH, ZC, JJ, DJ, VM, WH and TW have no relevant disclosures.
- 563

564 **<u>References:</u>**

- 1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.
- 566 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed
- 567 in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).

568 Eur Heart J 2021;42:373–498. doi:10.1093/eurheartj/ehaa612.

- 2. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An
- 570 increasing epidemic and public health challenge. International Journal of Stroke
- 571 2021;16:217–221. doi:10.1177/1747493019897870.

 $P_{age}23$

572	3.	Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent
573		stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med
574		2007;146:857-867. doi:10.7326/0003-4819-146-12-200706190-00007.
575	4.	Hermans ANL, Gawalko M, Dohmen L, van der Velden RMJ, Betz K, Duncker D, et
576		al. Mobile health solutions for atrial fibrillation detection and management: a
577		systematic review. Clin Res Cardiol 2022;111:479-491. doi:10.1007/s00392-021-
578		01941-9.
579	5.	Adasuriya G, Haldar S. Remote Monitoring of Cardiac Arrhythmias Using Wearable
580		Digital Technology: Paradigm Shift or Pipe Dream? Eur J Arrhythm Electrophysiol
581		2022;8:7. doi:10.17925/EJAE.2022.8.1.7.
582	6.	Gill S, Bunting K V, Sartini C, Cardoso VR, Ghoreishi N, Uh H-W, et al. Smartphone
583		detection of atrial fibrillation using photoplethysmography: a systematic review and
584		meta-analysis. Heart 2022;108:1600-1607. doi:10.1136/heartjnl-2021-320417.
585	7.	Castaneda D, Esparza A, Ghamari M, Soltanpur C, Nazeran H. A review on wearable
586		photoplethysmography sensors and their potential future applications in health care. Int
587		J Biosens Bioelectron 2018;4:195–202. doi:10.15406/ijbsbe.2018.04.00125.
588	8.	Piwek L, Ellis DA, Andrews S, Joinson A. The Rise of Consumer Health Wearables:
589		Promises and Barriers. PLoS Med 2016;13:e1001953.
590		doi:10.1371/journal.pmed.1001953.
591	9.	Conroy T, Guzman JH, Hall B, Tsouri G, Couderc J-P. Detection of atrial fibrillation
592		using an earlobe photoplethysmographic sensor. Physiol Meas 2017;38:1906–1918.
593		doi:10.1088/1361-6579/aa8830.

594 10. Nielsen IC. Lin Y-L de Oliveira Figueired	lo M.I. Sepehri Shamloo A. Alfie A. Boved	а
---	---	---

- 595 S, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society
- 596 (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm
- 597 Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the
- right tool for the right outcome,. EP Europace 2020;22:1147–1148.
- 599 doi:10.1093/europace/euaa065.
- 600 11. Briosa e Gala A, Pope MT, Leo M, Lobban T, Betts TR. NICE atrial fibrillation
- 601 guideline snubs wearable technology: a missed opportunity? Clin Med (Lond)
- 602 2022;22:77–82. doi:10.7861/clinmed.2021-0436.
- 603 12. Tudor-Locke C, Ducharme SW, Aguiar EJ, Schuna JM, Barreira T V., Moore CC, et
- al. Walking cadence (steps/min) and intensity in 41 to 60-year-old adults: the
- 605 CADENCE-adults study. International Journal of Behavioral Nutrition and Physical
 606 Activity 2020;17:137. doi:10.1186/s12966-020-01045-z.
- 13. Wong T, Haldar SK. Long-term Outcomes in Long Standing Persistent Atrial
- 608 Fibrillation (LoTO CASA AF) (Identifier NCT04280042). ClinicaltrialsGov 2020.
- 609 https://clinicaltrials.gov/ct2/show/NCT04280042 (accessed September 22, 2022).
- 610 14. Haldar S, Khan HR, Boyalla V, Kralj-Hans I, Jones S, Lord J, et al. Catheter ablation
- 611 vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation:
- 612 CASA-AF randomized controlled trial. Eur Heart J 2020;41:4471–4480.
- 613 doi:10.1093/eurheartj/ehaa658.
- 15. Sanders P, Pürerfellner H, Pokushalov E, Sarkar S, Di Bacco M, Maus B, et al.
- 615 Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable
- 616 cardiac monitor: Results from the Reveal LINQ Usability Study. Heart Rhythm
- 617 2016;13:1425–1430. doi:10.1016/j.hrthm.2016.03.005.

25

 $P_{age}25$

- 618 16. Ranjan Y, Rashid Z, Stewart C, Conde P, Begale M, Verbeeck D, et al. RADAR-Base:
- 619 Open Source Mobile Health Platform for Collecting, Monitoring, and Analyzing Data
- 620 Using Sensors, Wearables, and Mobile Devices. JMIR Mhealth Uhealth
- 621 2019;7:e11734. doi:10.2196/11734.
- 622 17. St. Jude Medical. The AF Effect on Quality of Life Survey (AFEQT). St Jude Medical,
- Inc 2023. /http://www.afeqt.org/ (accessed January 13, 2023).
- 624 18. Kotecha D, Breithardt G, Camm AJ, Lip GYH, Schotten U, Ahlsson A, et al.
- 625 Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA
- 626 Consensus Conference. EP Europace 2018;20:395–407. doi:10.1093/europace/eux318.
- 627 19. Chua S-K, Chen L-C, Lien L-M, Lo H-M, Liao Z-Y, Chao S-P, et al. Comparison of
- Arrhythmia Detection by 24-Hour Holter and 14-Day Continuous Electrocardiography
- 629 Patch Monitoring. Acta Cardiol Sin 2020;36:251–259.
- 630 doi:10.6515/ACS.202005_36(3).20190903A.
- 631 20. Xintarakou A, Sousonis V, Asvestas D, Vardas PE, Tzeis S. Remote Cardiac Rhythm
- 632 Monitoring in the Era of Smart Wearables: Present Assets and Future Perspectives.
- 633 Front Cardiovasc Med 2022;9. doi:10.3389/fcvm.2022.853614.
- 634 21. Perez M V., Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-
- 635 Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. New England Journal
- of Medicine 2019;381:1909–1917. doi:10.1056/NEJMoa1901183.
- 637 22. Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, et al. Mobile
- 638 Photoplethysmographic Technology to Detect Atrial Fibrillation. J Am Coll Cardiol
- 639 2019;74:2365–2375. doi:10.1016/j.jacc.2019.08.019.

Page 26

640	23.	Lubitz SA, Faranesh AZ, Atlas SJ, McManus DD, Singer DE, Pagoto S, et al.
641		Rationale and design of a large population study to validate software for the
642		assessment of atrial fibrillation from data acquired by a consumer tracker or
643		smartwatch: The Fitbit heart study. Am Heart J 2021;238:16–26.
644		doi:10.1016/j.ahj.2021.04.003.
645	24.	Aljuaid M, Marashly Q, AlDanaf J, Tawhari I, Barakat M, Barakat R, et al.
646		Smartphone ECG Monitoring System Helps Lower Emergency Room and Clinic
647		Visits in Post-Atrial Fibrillation Ablation Patients. Clin Med Insights Cardiol
648		2020;14:117954682090150. doi:10.1177/1179546820901508.
649	25.	Wu S, Li C, Lin J, Weng C, Lin W, Hsieh Y. Detecting supraventricular tachycardia
650		with smartwatches facilitates the decision for catheter ablation: A case series. Pacing
651		and Clinical Electrophysiology 2022;45:157–159. doi:10.1111/pace.14388.
652	26.	Siddeek H, Fisher K, McMakin S, Bass JL, Cortez D. AVNRT captured by Apple
653		Watch Series 4: Can the Apple watch be used as an event monitor? Annals of
654		Noninvasive Electrocardiology 2020;25. doi:10.1111/anec.12742.
655	27.	Kasai Y, Kasai J, Sekiguchi Y, Asano S, Fukunaga H, Nagase T, et al. Apple Watch®
656		facilitates single-session catheter ablation of coexisting atrioventricular nodal reentrant
657		tachycardia and atrioventricular reentrant tachycardia. Clin Case Rep 2021;9.
658		doi:10.1002/ccr3.4702.
659	28.	Passman R. "Pill-in-Pocket" Anticoagulation for Atrial Fibrillation: Fiction, Fact, or
660		Foolish? Circulation 2021;143:2211–2213.
661		doi:10.1161/CIRCULATIONAHA.121.053170.

Page 27

662	29.	Rizas KD, Freyer L, Sappler N, von Stülpnagel L, Spielbichler P, Krasniqi A, et al.
663		Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical
664		trial. Nat Med 2022;28:1823–1830. doi:10.1038/s41591-022-01979-w.
665	30.	Kwon S, Choi EK, Lee SR, Ahn HJ, Lee B, Oh S, et al. Atrial fibrillation detection in
666		ambulatory patients using a smart ring powered by deep learning analysis of
667		continuous photoplethysmography monitoring. Eur Heart J 2022;43.
668		doi:10.1093/eurheartj/ehac544.415.
669	31.	Betts T. Continuous Rhythm Monitoring With Implantable Cardiac Monitors And
670		Wearable Devices With Real-time Smartphone Alerts During AF Episodes (SMART-
671		ALERT). ClinicalTrialsGov 2023.
672		https://www.clinicaltrials.gov/ct2/show/NCT05207150 (accessed January 11, 2023).
673	32.	Williams K, Modi RN, Dymond A, Hoare S, Powell A, Burt J, et al. Cluster
674		randomised controlled trial of screening for atrial fibrillation in people aged 70 years
675		and over to reduce stroke: protocol for the pilot study for the SAFER trial. BMJ Open
676		2022;12:e065066. doi:10.1136/bmjopen-2022-065066.
677	33.	Andrade JG, Shah A, Godin R, Lanitis T, Kongnakorn T, Brown L, et al. Cost-
678		effectiveness of atrial fibrillation screening in Canadian community practice. Heart
679		Rhythm O2 2022. doi:10.1016/j.hroo.2022.11.003.
680	34.	Chen W, Khurshid S, Singer DE, Atlas SJ, Ashburner JM, Ellinor PT, et al. Cost-
681		effectiveness of Screening for Atrial Fibrillation Using Wearable Devices. JAMA
682		Health Forum 2022;3:e222419. doi:10.1001/jamahealthforum.2022.2419.
683	35.	Kim SH, Lim KR, Seo J-H, Ryu DR, Lee B-K, Cho B-R, et al. Higher heart rate
684		variability as a predictor of atrial fibrillation in patients with hypertension. Sci Rep
685		2022;12:3702. doi:10.1038/s41598-022-07783-3.

 ${}^{\rm Page}28$

686	36.	Fine J, Branan KL, Rodriguez AJ, Boonya-ananta T, Ajmal, Ramella-Roman JC, et al.
-----	-----	---

- 687 Sources of Inaccuracy in Photoplethysmography for Continuous Cardiovascular
- 688 Monitoring. Biosensors (Basel) 2021;11:126. doi:10.3390/bios11040126.
- 689 37. Chokesuwattanaskul R, Safadi AR, Ip R, Waraich HK, Hudson OM, Ip JH. Data
- 690 Transmission Delay in Medtronic Reveal LINQ Implantable Cardiac Monitor: Clinical
- Experience in 520 Patients. J Biomed Sci Eng 2019;12:391–399.
- 692 doi:10.4236/jbise.2019.128030.
- 693 38. Gill SK, Karwath A, Uh H-W, Cardoso VR, Gu Z, Barsky A, et al. Artificial
- 694 intelligence to enhance clinical value across the spectrum of cardiovascular healthcare.
- 695 Eur Heart J 2023;44:713–725. doi:10.1093/eurheartj/ehac758.

696

697 <u>Tables</u>:

Table 1: Inclusion and exclusion criteria for REMOTE-AF. LoTO in CASA LSPAF = Long term outcomes in long standing persistent atrial fibrillation RCT (ClinicalTrials.gov Identifier: NCT04280042). ILR = implantable loop recorder.

Inclusion Criteria	Exclusion Criteria
• Participants in LoTO in CASA LSPAF with working ILRs or implanted devices capable of continuous rhythm monitoring.	 Participants in LoTO in CASA LSPAF without working ILRs or implanted devices capable of continuous rhythm monitoring. Recurrence of Persistent AF. Lack of weekly access to internet or charging facilities.

Table 2. Baseline characteristics of REMOTE-AF study participants

70

AF, atrial fibrillation; AFEQT, AF quality of life survey; BMI, body mass index; CHA₂DS₂VASc,
congestive heart failure, high blood pressure, Age 75, Diabetes, previous Stroke or clot, Vascular disease, Age 65–74, Sex; HASBLED, hypertension; Abnormal liver/renal function, Stroke history, Bleeding history or predisposition, Labile INR (international normalized ratio), Elderly, Drug/alcohol usage; IQR, interquartile range; SD, standard deviation; TIA, transient ischaemic attack.

 $P_{\text{BBe}}29$

		All			
	Characteristics	(n = 35)	Recurrence (<i>n</i> = 17)	No recurrence (<i>n</i> = 18)	
7(Age (years), mean (SD)	71 (6.8)	71 (6.31)	69 (7.2)	
71	>/= 75, n (%)	10 (28.6)	5 (29.4)	5 (27.8)	
	65-74	18 (51.4)	7 (41.2)	11 (61.1)	
71	55-64	6 (17.1)	4 (23.5)	2 (33.3)	
7	40-54	1 (2.9)	1 (5.9)	0 (0)	
	Male sex, n (%)	23 (65.7)	9 (52.9)	14 (77.8)	
7:	BMI (kg/m ²), median (IQR)	30.4 (25.3–33.27)	26.9 (25–33)	30.9 (28.5–33.3)	
	Ethnicity, n (%)				
7:	White	35 (100)	17 (100)	18 (100)	
	Ejection fraction (%), mean (SD)	56.9 (8.9)	55.2 (8.9)	58.8 (8.7)	
7:	Left atrial diameter (mm), mean (SD)	44.6 (5.9)	44.6 (6)	44.7 (5.8)	
7:	Index procedure, <i>n</i> (%)	16 (45 7)	7 (41.0)	0 (70)	
	Thoracascopic surgical abla- tion	16 (45.7)	7 (41.2)	9 (50)	
7:	Radiofrequency catheter abla- tion	19 (54.3)	10 (58.8)	9 (50)	
7:	Time from index procedure (months), mean (SD)	34 (7.8)	33 (5.5)	37 (6.5)	
	AFEQT score, mean (SD)	46 (21)	44 (15)	48 (25)	
7:	Hypertension	13 (37.1)	8 (47.1)	5 (27.8)	
7	Diabetes	3 (8.6)	1 (5.9)	2 (11.1)	
1.	Coronary artery disease	2 (5.7)	1 (5.9)	1 (5.6)	
7 :	Stroke, TIA, Thromboembo- lism	3 (8.6)	2 (11.8)	1 (5.6)	
	Heart Failure	3 (8.6)	2 (11.8)	1 (5.6)	
7:	CHA_2DS_2VASc score, n (%)				
7:	0	2 (5.7)	1 (5.9)	1 (5.6)	
7.	1	10 (28.6)	5 (29.4)	5 (27.8)	
7.	2	11 (31.4)	5 (29.4)	6 (33.3)	
7:	≥3	12 (34.3)	6 (35.3)	6 (33.3)	
7:	HASBLED score, n (%)				
.	0	1 (2.9)	0 (0)	1 (5.6)	
7.	1	9 (25.7)	6 (35.3)	3 (16.7)	
7:	2	22 (62.9)	10 (58.9)	12 (66.7)	
	≥3	3 (8.6)	1 (5.9)	2 (11.1)	

 ${}^{\rm Page}30$

Table 3: Results table showing sensitivity, specificity, positive predictive value (PPV), negativepredictive value (NPV) and accuracy for each stepwise combination of wearable device data.

	Sensitivity	Specificity	PPV	NPV	Accuracy
	(%)	(%)	(%)	(%)	(%)
Heart Rate	95.3	54.1	15.8	99.2	57.4
Heart Rate and Step Count	93.2	54.9	19.1	98.6	58.7
Heart Rate spike score and Step Count	87.5	62.2	39.2	92.3	64.0
HR spike score and Step Count in recurrence group	87.6	68.3	53.6	93.0	74.0









 ${}^{\text{Page}}34$



Figure 5: Illustration to show sensitivity, specificity and PPV of smart devices in detecting recurrence of atrial arrhythmias in post intervention patient cohorts compared with gold standard ILR compared to our data.

827

A. REMOTE-AF data from 35 patients. B. ECG based detection post ablation in study of 99 patients.²⁴. C. Smart ring-based detection of atrial arrhythmia post DCCV in study of 35 patients.³⁰

- ILR = implantable loop recorder. DCCV = direct current cardioversion.
- 829

